Search results
Results from the WOW.Com Content Network
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
A decision on donanemab has been delayed, with the regulatory agency initially planning to make a call in July, the same time it was approved for use in the U.S., the report said.
Donanemab, also known as Kisunla, was found to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% reduction in the decline of ...
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [31] [32] Donanemab was developed by Eli Lilly and Company. [33] [34] The most common side effects include amyloid-related imaging abnormalities and headache. [32] Donanemab was approved for medical use in the United States in ...
Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its ...
Here are links to possibly useful sources of information about Donanemab. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC
Donanemab is a monoclonal antibody that binds to a protein that builds up in the brain during the early stages of Alzheimer’s. According to Alzheimer’s Society, the drug is a disease-modifying ...
The Food and Drug Administration has pushed back its approval decision deadline for Eli Lilly’s experimental Alzheimer’s drug donanemab. In an unusual move, FDA postpones approval decision for ...